EKZ-102

Asset

Brain-penetrant HDAC6 inhibitor designed to achieve neuroprotection.

Stage: Preclinical
Modality: Small molecule
Target: HDAC6; 1
Indication: 0
Trials: 1
Developer

Indications

1

Amyotrophic lateral sclerosis
Preclinical, eikonizo.com, 10 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Evidence for its targets1
Competitors12

Every asset’s record: target, stage, trials and the evidence behind it.